PPAR␥ is activated by diverse ligands and regulates the differentiation of many cell types. Based on evidence that activation of PPAR␥2 by rosiglitazone stimulates adipogenesis and inhibits osteoblastogenesis in U-33/␥2 cells, a model mesenchymal progenitor of adipocytes and osteoblasts, we postulated that the increase in marrow fat and the decrease in osteoblast number that occur during aging are due to increased PPAR␥2 activation. Here, we show that the naturally occurring PPAR␥ ligands 9,10-dihydroxyoctadecenoic acid, and 15-deoxy-⌬ 12,14 -PGJ 2 , also stimulate adipocytes and inhibit osteoblast differentiation of U-33/␥2 cells. Strikingly, 9,10-epoxyoctadecenoic acid and the thiazolidine acetamide ligand GW0072 [(؎)-(2S,5S)-4-(4-(4-carboxyphenyl)butyl)-2-heptyl-4-oxo-5-thaizolidine N,N-dibenzyl-acetamide] prevent osteoblast differentiation, but do not stimulate adipogenesis, whereas 9-hydroxyoctadecadienoic acid stimulates adipogenesis but does not affect osteoblast differentiation. The divergent effects of PPAR␥2 ligands on osteoblast and adipocyte differentiation were confirmed in primary murine bone marrow cultures using rosiglitazone and GW0072. These findings indicate that the proadipogenic and antiosteoblastogenic effects of PPAR␥2 are mediated by distinct regulatory pathways that can be differentially modulated depending on the nature of the ligand, and they support the idea that increased fatty acid oxidation during aging may inhibit osteoblast differentiation. Moreover, there may be selective PPAR␥2 modulators that block the adverse effects of fatty acid oxidation products while retaining beneficial activities such as insulin sensitization. (Endocrinology 143: 2376 -2384, 2002) P PAR␥ is a member of the nuclear receptor family of transcription factors, a large and diverse group of proteins that mediate ligand-dependent transcriptional activation or repression (1). PPAR␥ exists in two isoforms, PPAR␥1 and PRAR␥2, as a result of alternative promoter usage and alternative splicing. PPAR␥ plays an important role in adipogenesis and glucose homeostasis, and has also been implicated in inflammatory responses, atherosclerosis, and cancer (1-3). This diverse spectrum of activities appears to be due to the cell specificity of PPAR␥ function and the nature of the ligand (4 -6). Indeed, the ligand-binding domain of PPAR␥ is quite promiscuous and interacts with a wide variety of substances, including thiazolidinediones, modified tyrosine and leucine derivatives, PGJ 2 metabolites, polyunsaturated fatty acids and their oxidation products, and certain alkyl phospholipids (7-13).
whereas 9-hydroxyoctadecadienoic acid stimulates adipogenesis but does not affect osteoblast differentiation. The divergent effects of PPAR␥2 ligands on osteoblast and adipocyte differentiation were confirmed in primary murine bone marrow cultures using rosiglitazone and GW0072. These findings indicate that the proadipogenic and antiosteoblastogenic effects of PPAR␥2 are mediated by distinct regulatory pathways that can be differentially modulated depending on the nature of the ligand, and they support the idea that increased fatty acid oxidation during aging may inhibit osteoblast differentiation. Moreover, there may be selective PPAR␥2 modulators that block the adverse effects of fatty acid oxidation products while retaining beneficial activities such as insulin sensitization. (Endocrinology 143: 2376 -2384, 2002) P PAR␥ is a member of the nuclear receptor family of transcription factors, a large and diverse group of proteins that mediate ligand-dependent transcriptional activation or repression (1) . PPAR␥ exists in two isoforms, PPAR␥1 and PRAR␥2, as a result of alternative promoter usage and alternative splicing. PPAR␥ plays an important role in adipogenesis and glucose homeostasis, and has also been implicated in inflammatory responses, atherosclerosis, and cancer (1) (2) (3) . This diverse spectrum of activities appears to be due to the cell specificity of PPAR␥ function and the nature of the ligand (4 -6) . Indeed, the ligand-binding domain of PPAR␥ is quite promiscuous and interacts with a wide variety of substances, including thiazolidinediones, modified tyrosine and leucine derivatives, PGJ 2 metabolites, polyunsaturated fatty acids and their oxidation products, and certain alkyl phospholipids (7) (8) (9) (10) (11) (12) (13) .
The ability of PPAR␥2 to stimulate adipocyte differentiation is of relevance to skeletal metabolism because of evidence that marrow fat increases with age in both animals and humans concomitant with a fall in osteoblast production (14 -16) . Because marrow adipocytes and osteoblasts are derived from a common mesenchymal progenitor (17) , we have proposed that the bone loss commonly seen during aging in both males and females is due in part to a reciprocal increase in the development of adipocytes and a decrease in osteoblast differentiation. In support of this contention, we have previously demonstrated that activation of PPAR␥2 with rosiglitazone in the murine marrow-derived mesenchymal progenitor cell line U-33/␥2 stimulated their differentiation to adipocytes and irreversibly blocked their ability to differentiate into osteoblasts (18) . The latter response appeared to be due to the suppression of runt-related transcription factor 2/core-binding factor-␣1 (Runx2/Cbfa1; also known as AML3 and PEBP2␣A), a transcription factor required for osteoblast differentiation (19) , and the synthesis of osteoblast-specific proteins such as alkaline phosphatase, osteocalcin, osteopontin, and ␣1(I)-procollagen (20) . Thus, PPAR␥2 is a potent suppressor of the osteoblast phenotype and may be critically involved in the differentiation of bone marrow mesenchymal progenitors toward adipocytes. Based on this, it is likely that the age-related increase in adipocyte and the decrease in osteoblast differentiation may be due to increased activation of PPAR␥2. The fact that fatty acid oxidation products can bind and activate PPAR␥2, together with evidence for their increased production with advancing age (21) , suggests that they could contribute to the increased fat and bone loss that characterize the aging skeleton.
Here we compared a variety of PPAR␥ ligands for their ability to influence differentiation of U-33/␥2 cells to adipocytes or osteoblasts. We found that the linoleic acid (LA) peroxidation products 9,10-epoxyoctadecenoic acid (9,10-EOA) and 9,10-dihydroxyoctadecenoic acid (9,10-DHOA) are PPAR␥2 ligands, and that 9,10-DHOA is both proadipocytic and antiosteoblastic. Strikingly, however, 9,10-EOA and the thiazolidine acetamide ligand GW0072 [(Ϯ)-(2S,5S)-4-(4-(4-carboxyphenyl)butyl)-2-heptyl-4-oxo-5-thaizolidine N,N-dibenzyl-acetamide] are antiosteogenic without stimulating adipocyte differentiation. On the other hand, 9-hydroxyoctadecadienoic acid (9-HODE) is proadipogenic without affecting osteoblast differentiation. These findings indicate that PPAR␥2 stimulates multiple pathways that promote adipocyte differentiation, inhibit osteoblast differentiation, or both depending on the nature of the ligand, and that fatty acid oxidation metabolites could be involved in age-related bone loss.
Materials and Methods Materials
Rosiglitazone (BRL 49653) was obtained from Tularik, Inc. (South San Francisco, CA); GW0072 was obtained from GlaxoSmithKline Pharmaceuticals (Research Triangle Park, NC); 15-deoxy-⌬ 12,14 -PGJ 2 (15dPGJ 2 ) and 9(S)HODE were purchased from Cayman Chemical (Ann Arbor, MI), and LA was from Sigma (St. Louis, MO). 9,10-EOA and 9,10-DHOA were synthesized as previously described (22) . At the concentrations used in the experiments none of the compounds tested for their effect on cell differentiation had an effect on cell viability as measured by trypan blue exclusion; however, oxidized fatty acids caused cell toxicity at higher than tested concentrations.
Ligand binding to PPAR␥
The binding affinities of 9,10-EOA, 9,10-DHOA, and LA were determined using a previously described scintillation proximity assay (SPA; Amersham Pharmacia Biotech, Piscataway, NJ) (23) . Briefly, the PPAR␥ ligand-binding domain was expressed in Escherichia coli as a glutathione-S-transferase-tagged fusion protein. The protein was purified and immobilized on poly-l-lysine-coated yttrium silicate SPA beads. The labeled PPAR␥ ligand 
Differentiation of U-33/␥2 cells
Murine marrow-derived UAMS-33 cells stably transfected with a vector expressing mRNA for PPAR␥2, referred to as U-33/␥2 cells, and UAMS-33 cells transfected with an empty vector control, referred to as U-33/c cells, have been previously described (18) . In the former, PPAR␥2 transcription is under the control of a promoter fragment of human EF-1␣ translation elongation factor. The level of PPAR␥2 protein is comparable to that seen in a marrow-derived adipocyte cell line (18) . To avoid artifacts due to potential differences among PPAR␥2 stable transfectants, all experiments were performed using two independently derived clones, ␥2.28 and ␥2.45 (18) . Representative data from clone ␥2.28 are shown in this report. Cells were maintained in ␣MEM supplemented with 10% FBS (HyClone Laboratories, Inc., Logan, UT), 0.5 mg/ml G418, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin (Sigma) at 37 C in a humidified atmosphere containing 5% CO 2 For analysis of osteoblast differentiation, the cells were initially cultured for 6 d without or with ligands as described above and then maintained for an additional 13 d in medium without ligands but containing 0.2 mm ascorbic acid (Sigma) and 10 mm ␤-glycerophosphate (Sigma) to stimulate osteoblast differentiation (18) . The culture medium was replaced every other day. Calcium deposited into the extracellular matrix, a marker of differentiated osteoblasts, was extracted with 0.1% acetic acid for 5 h at room temperature and quantified colorimetrically using calcium-binding reagent (Sigma).
Differentiation of bone marrow-derived mesenchymal progenitors
Bone marrow cells were obtained from adult Swiss-Webster mice and maintained in the presence of ␣MEM with 15% FBS and 1 mm ascorbate-2-phosphate at 1.5 ϫ 10 6 /10-cm 2 culture dish as previously described (24 
Northern and RT-PCR analysis of gene expression
Total RNA was isolated using an RNAeasy kit (QIAGEN, Chatsworth, CA). The following cDNA probes were used for detection of transcripts on Northern blots: a 1.8-kb fragment of human CAAT enhancer-binding protein-␣ (C/EBP␣), a 1.4-kb fragment of murine lipoprotein lipase (LPL), a 0.6-kb fragment of murine fatty acid-binding protein aP2, a 1.5-kb fragment of murine osteopontin, and a 1.5-kb fragment of human ␣1(I)-procollagen. The human probes were more than 80% homologous to the murine sequences. Transcripts were visualized with a phosphorimager. The equivalence of loading and transfer of RNA onto membranes was assessed by detection of 18S rRNA using human cDNA as a probe. All hybridizations were performed under high stringency conditions as previously described (25) .
RT-PCR was performed using Advantage RT-for-PCR and Advantage cDNA PCR kits (CLONTECH Laboratories, Inc., Palo Alto, CA). The RT reaction was incubated at 42 C for 1 h. The amount of cDNA used for each PCR corresponded to the 0.014 g total RNA used originally for the RT reaction. The amplification reactions were performed using the following primers and protocols: Runx2/Cbfa1: forward, 5Ј-CTA-CAACCTTGAAGGCCACG-3Ј; reverse, 5Ј-ATGCTTCATTCGCCTCA-CAAAC-3Ј (annealing at 60 C; 35 cycles; product, 655 bp) (26); Wnt-10b: forward, 5Ј-CTGCCACTGTCGTTTCCACTG-3Ј; reverse, 5Ј-AGAC-CCTTTCAACAACTGAACG-3Ј (annealing at 60 C; 32 cycles; product, 660 bp); glyceraldehyde-3-phosphate dehydrogenase: forward, 5Ј-AT-TGGGAAGCTTGTCATCAACG-3Ј; reverse, 5Ј-CACCCTGTTGCTG-TAGCCGT-3Ј (annealing at 60 C; 23 cycles; product, 781 bp). Reactions were carried out using a Perkin-Elmer Corp./Cetus DNA Thermal Cycler (Norwalk, CT). PCR products were resolved on 2% ultraPURE agarose (Life Technologies, Inc.). Preliminary experiments varying the amount of template between 0.05 and 0.005 g RNA and the number of cycles showed that the reaction products generated under the conditions described above for each transcript were within the linear range of the amplification.
Transient transfection and trans-activation assay
Transfections were performed using Lipofectamine Plus reagent (Life Technologies, Inc.). Typically, cells were plated in triplicate at the density of 3 ϫ 10 4 cells/1.8-cm 2 well and transfected for 6 h with 0.4 g DNA of firefly luciferase gene reporter constructs (Promega Corp., Madison WI) under the transcriptional control of either peroxisome proliferator response element (PPRE) sequences in a 2AOx construct (27) or osteoblast-specific element 2 (OSE2) sequences in a 1.3luc construct (28) . The 2AOx construct has two copies of PPRE from the acetyl-coenzyme A oxidase gene promoter introduced into the minimal promoter from the rat liver carbamoyl-phosphate synthetase gene. Cells were cotransfected with 0.2 g DNA of pRL-TK vector encoding Renilla luciferase enzyme (Promega Corp.). Then, the medium was changed, and the cells were cultured with vehicle or PPAR␥ ligand for 24 h. The firefly and Renilla luciferase activities were detected using the Dual Luciferase Reporter Assay (Promega Corp.). Firefly luciferase activity was normalized with Renilla luciferase activity. Each experiment was repeated three times. 50 values using logistic regression. ANOVA and post hoc testing for significant differences by the Bonferroni method were used to demonstrate dose-dependent effects of ligands on adipocyte and osteoblast differentiation. In all cases, P Ͻ 0.05 was considered significant.
Results

Binding affinity of tested compounds
Several PPAR␥ ligands were tested for their ability to influence adipocyte and osteoblast differentiation (see Table  1 ). They included the established PPAR␥ ligands rosiglitazone and 15dPGJ 2 , and GW0072, a PPAR␥ modulator that blocks the stimulatory effect of rosiglitazone on adipogenesis (29) . In addition, the effects of LA and its oxidation products, 9-HODE, 9,10-DHOA, and 9,10-EOA, were studied. The latter two compounds are found in vivo (21, 30) and are potential PPAR␥ ligands based on their structural similarity to LA. Both 9,10-DHOA and 9,10-EOA displaced the thiazolidinedione radioligand [ 3 H]T0900393 from PPAR␥, as determined by SPA (Fig. 1) . The IC 50 values for 9,10-DHOA and 9,10-EOA were 2.8 Ϯ 1.0 and 0.8 Ϯ 0.6 m, respectively. The LA IC 50 value of 2.9 Ϯ 0.2 m (Ϯsem) was similar to that previously reported (23) .
Effects of ligands on adipocyte and osteoblast development
The effects of various PPAR␥ ligands on adipocyte and osteoblast differentiation were studied in the model bipotential mesenchymal progenitor cell line U-33/␥2 stably transfected with a PPAR␥2 expression construct (18) . U-33/c cells that do not express PPAR␥2 served as a negative control. In the presence of ascorbic acid and ␤-glycerophosphate, both cell lines express an osteogenic phenotype, whereas addition of the PPAR␥ ligand rosiglitazone induces fat accumulation and irreversibly suppresses the osteoblast phenotype only in U-33/␥2 cells (18) . Figure 2A shows that of those ligands that stimulated lipid accumulation, they did so in rank order of their affinity for PPAR␥ (rosiglitazone Ͼ 15dPGJ 2 Ͼ 9(S)-HODE ϳ 9,10-DHOA). LA, 9,10-EOA, and GW0072 did not stimulate lipid accumulation. In experiments not presented here, GW0072 antagonized rosiglitazone-stimulated adipogenesis, consistent with a previous report (29) . Practically all of the cells were converted to adipocytes by rosiglitazone at concentrations of 1 m or more. Maximal concentrations of rosiglitazone and 15dPGJ 2 induced accumulation of large fatcontaining droplets within the cells, and the cells changed from a fibroblastic to a rhomboid morphology (Fig. 3) . Doses of rosiglitazone as low as 0.01 m, which is below its K d for PPAR␥ (Table 1) , caused the appearance of fat in approximately 50% of treated cells; however, the size of fat droplets was smaller than after the same time of treatment with intermediate concentrations of the ligand (not shown). As we did not attempt to quantify the amount of fat per cell, low and intermediate levels of rosiglitazone thus appeared to be of equivalent potency in this assay.
Compared with rosiglitazone, the degree of maximal adipogenesis stimulation achieved by 15dPGJ 2 , 9-HODE, and 9,10-DHOA was significantly lower. This may be due to the comparatively lower stability of these ligands in aqueous media compared with rosiglitazone and binding to the serum albumin (Grant, D., unpublished observations). Fat droplets in cells treated with 9-HODE or 9,10-DHOA were small, and the cells retained their fibroblastic appearance (Fig. 3) . Figure 2B shows that rosiglitazone and 15dPGJ 2 , which induced adipogenesis, also inhibited mineral deposition. However, GW0072 and 9,10-EOA, which did not influence adipogenesis, did inhibit mineral deposition, whereas 9-HODE, which stimulated fat accumulation, failed to suppress mineral deposition. As in the case of adipogenesis, LA had no effect on osteoblast differentiation. In data not shown here, we found that none of the tested compounds stimulated fat accumulation or inhibited mineralization in cultures of U-33/c cells, indicating that the effects on adipocyte and osteoblast differentiation are PPAR␥2 dependent.
To confirm divergent effects of different PPAR␥2 ligands on osteoblast and adipocyte differentiation, we compared the effects of rosiglitazone and GW0072 on murine marrow-derived mesenchymal progenitors (Table 2) . In these cultures, early mesenchymal progenitors replicate to form a colony of cells that can differentiate into osteoblasts and/or adipocytes upon exposure to appropriate FIG. 1. Binding of LA and LA oxidation products to PPAR␥. The abilities of LA, 9,10-DHOA, and 9,10-EOA to bind to PPAR␥ were determined by displacement of the thiazolidinedione ligand [ 3 H]T0900393 using SPA. The displacement curves shown were calculated by logistic regression, and gave IC 50 values of 2.9 Ϯ 0.2 M (ϮSEM) for LA, 2.8 Ϯ 1.0 M for 9,10-DHOA, and 0.8 Ϯ 0.6 M for 9,10-EOA.
prodifferentiating agents (17, 24) . We found that both ligands modestly reduced the total number of colonies that developed in the cultures. Nevertheless, and consistent with the findings in the U-33/␥2 cell model, only rosiglitazone stimulated adipocyte differentiation in these cultures, whereas both ligands strongly suppressed osteoblast differentiation.
Effects of ligands on the expression of phenotype-specific genes and trans-activation of PPRE and OSE2 regulatory elements
We next examined the effect of each ligand on the expression of genes associated with the development and/or expression of the adipocyte or osteoblast phenotype. Northern blot analysis showed that all ligands, except LA, stimulated the expression of C/EBP␣ and LPL, early markers of adipogenesis (Fig. 4A) . However, only rosiglitazone and 15dPGJ 2 stimulated aP2 mRNA expression, a marker of fully differentiated adipocytes. Consistent with these findings, only these two ligands were able to activate PPRE of the acetylCoA oxidase promoter in a reporter gene assay (Fig. 5A) (27) . Activation of PPRE was PPAR␥2 dependent, as evidenced by the lack of effect of any ligand when the reporter gene was transfected into PPAR␥2-negative U-33/c cells.
Semiquantitative RT-PCR analysis showed that rosiglitazone, 15dPGJ 2 , and GW0072 strongly suppressed the expression of Wnt-10b, a negative regulator of adipocyte formation (Fig. 4B) (31) . Marginal inhibitory effects of 9-HODE and LA were also noted, but 9,10-DHOA and 9,10-EOA failed to inhibit Wnt-10b expression. These effects were PPAR␥2 dependent, as they were observed in U-33/␥2 cells, but not in U-33/c control cells.
Every ligand that inhibited calcium deposition by U-33/␥2 cells also suppressed expression of ␣1(I)-procollagen mRNA; The percentage of cells containing fat was then determined after staining with Oil Red O as described in Materials and Methods. B, Osteoblastogenesis. Cells were cultured and exposed to compounds as described in A. The cells were then rinsed and medium was replaced with proosteoblastogenic medium for an additional 13 d. Osteoblast differentiation was quantified by determining the calcium content in each well. ANOVA and post hoc testing for significant differences using the Bonferroni method demonstrated dose-dependent effects of specific ligands on lipid accumulation (rosiglitazone, 15dPGJ 2 , 9-HODE, and 9,10-DHOA) and on mineral deposition (rosiglitazone, GW0072, 15dPGJ 2 , 9,10-DHOA, and 9,10-EOA). however, osteopontin mRNA levels were significantly affected only by rosiglitazone and 15dPGJ 2 (Fig. 4A) . Interestingly, 9-HODE, which did not significantly inhibit calcium deposition, also decreased ␣1(I)-procollagen mRNA. Expression of Runx2/Cbfa1 was inhibited by rosiglitazone and 15dPGJ 2 , but GW0072, 9,10-EOA, and 9,10-DHOA, which inhibited mineralization, did not affect Runx2/Cbfa1 expression (Fig. 4B) . LA and 9-HODE, which did not exert antiosteoblastic activity, also did not affect Runx2/Cbfa1 expression.
Finally, we examined the effects of the ligands on the activity of the osteoblast-specific osteocalcin promoter. Cells were transiently transfected with a construct comprising the OSE2 of the rat osteocalcin promoter driving the expression of luciferase (28) . As shown in Fig. 5B, rosiglitazone, 15dPGJ 2 , and GW0072 suppressed osteocalcin promoter activity in U-33/␥2, but not in U-33/c, cells, whereas LA and its oxidized metabolites had no effect.
Discussion
PPAR␥2 modulates numerous physiological and pathological processes. The findings presented herein show that, depending on the activating ligand, PPAR␥2 may stimulate adipocyte differentiation, suppress osteoblast differentiation, or exhibit both activities in U-33/␥2 cells, a model bipotential mesenchymal progenitor cell line. These effects were mediated by PPAR␥2, as evidenced by the fact that U-33/c cells lacking PPAR␥2 failed to respond to any of the ligands tested. The same divergent effects of two of the ligands, namely rosiglitazone and GW0072, were confirmed in primary cultures of murine marrow-derived mesenchymal progenitors. Reminiscent of our findings in marrow stromal cells, previous studies have demonstrated that different PPAR␥ ligands exert disparate effects on macrophage differentiation (32) (33) (34) .
Osteoblasts and marrow adipocytes originate from a common mesenchymal progenitor. Lineage commitment probably depends on specific transcription factors that simultaneously suppress factors that are required for expression of the alternate phenotype. Previous experiments with cell lines, primary marrow-derived stromal cell cultures, as well as in vivo studies in rodents and humans have provided evidence indicating that proadipogenic agents suppress osteoblast differentiation (18, (35) (36) (37) (38) (39) . However, we found that whereas rosiglitazone, 15dPGJ 2 , and 9,10-DHOA activate both proadipogenic and antiosteoblastogenic pathways, GW0072 and 9,10-EOA inhibit osteoblast differentiation without activating adipocyte differentiation, and 9-HODE stimulates lipid accumulation, but has no effect on osteogenesis. Therefore, reciprocal changes in adipogenesis and osteoblastogenesis are not an inevitable consequence of PPAR␥2 activation.
Rosiglitazone and 15dPGJ 2 activated pathways that are functionally distinct from those of LA metabolites to stimulate adipocyte differentiation. Thus, rosiglitazone and 15dPGJ 2 induced the complete spectrum of adipogenic responses, including activation of a PPRE and expression of early (C/EBP␣ and LPL) and late (aP2) markers of adipocyte differentiation. As shown here for the first time, both ligands also down-regulated Wnt-10b expression, as would be expected from evidence that Wnt-10b prevents expression of the adipocyte phenotype (31) . Interestingly, however, GW0072 also suppressed Wnt-10b, but had no effect on adipogenesis, indicating only partial activation of PPAR␥2 by this ligand. In contrast, none of the LA oxidation products activated PPRE or induced aP2 mRNA, but they did stimulate C/EBP␣ and LPL synthesis, which are necessary for adipocyte development and function (40) . Recent evidence indicates that expression of aP2 mRNA is governed by a PPRE and controls certain adipocyte functions, but it is not required for adipocyte differentiation (41, 42) . Therefore, thiazolidinediones and 15dPGJ 2 may promote the development of marrow adipocytes that are functionally distinct from those induced by oxidized fatty acids.
Distinct pathways are also involved in suppression of the osteoblastic phenotype by various PPAR␥2 ligands. This is in keeping with the fact that full expression of the osteoblast phenotype depends not only on Runx2/Cbfa1 and other transcriptional regulators (43) (44) (45) , but also on integrin signaling generated by interaction with collagen in the extracellular matrix (46) . Thus, the loss of such signaling by downregulation of ␣1(I)-procollagen expression in response to PPAR␥2 activation may contribute to the suppression of osteogenesis. Inhibition of osteoblast differentiation by rosiglitazone and 15dPGJ 2 was associated with the reduction of Runx2/Cbfa1, ␣1(I)-procollagen, and reduced OSE2 promoter activity. GW0072 strongly inhibited both OSE2 activity and ␣1(I)-procollagen expression, responses that were not apparently mediated by down-regulation of Runx2/Cbfa1 expression. It is possible that GW0072 exerts its effect by interfering with, or down-regulating, other transcriptional regulators, such as Msx2, Dlx5, or osterix, which are also required for OSE2 activity (44, 47, 48) . Further, the most potent antiosteogenic ligands (rosiglitazone, 15dPGJ 2 , and GW0072) almost completely abrogated the expression of Wnt- 10b, an activator of frizzled/low density lipoprotein (LDL) receptor-related protein receptors leading to ␤-catenin-mediated changes in gene expression (49) . It was recently shown that mutations in the LDL receptor-related protein-5 component of the receptor affect bone accrual in human and rodents (50, 51) , and that Wnt-induced ␤-catenin signaling can stimulate osteoblast differentiation in vitro (52) (53) (54) . Thus, the ability of these PPAR␥2 ligands to inhibit Wnt-10b synthesis may also contribute to their ability to inhibit osteogenesis.
What could explain the ligand-dependent effects of PPAR␥2 activation reported herein? As in the case of other members of the nuclear receptor family of transcription factors, ligand binding to PPAR␥ induces allosteric alterations of the activating function-2 domain, resulting in dissociation of transcriptional corepressors and concomitant association of transcriptional coactivators (55) . However, different coactivators may be recruited depending on the ligand (4 -6, 56). For example, it has been reported that rosiglitazone and 15dPGJ 2 recruited similar coactivators to the complex, including SRC-1, CBP/p300, and TRAP220/DRIP205, whereas 9-HODE did not (5, 6) (55). On the other hand, GW0072 exhibited limited capacity to recruit SRC-1 and CBP/p300 compared with rosiglitazone (29) . It is also important to consider activation of nongenotropic intracellular signaling, as has been observed for several members of the nuclear receptor family, including ER, AR, VDR, and PR (57) . Of relevance to the present discussion, ligand-specific activation of the genomic vs. nongenomic actions of the ER has been demonstrated with structurally different ligands, an estren and a pyrazole, respectively (58) . In view of this, it is tempting to speculate that PPAR␥2-mediated activation of nongenomic pathways can partially account for the divergent effects of PPAR␥2 ligands reported in our studies.
Our results demonstrate that two LA oxidation products, 9,10-EOA and 9,10-DHOA, are ligands for PPAR␥2, and they both inhibit osteoblast differentiation. These effects required high concentrations of the free acids in our culture system, perhaps due to their binding to serum proteins and/or instability in aqueous media. However, these metabolites are components of oxidized LDL, the level of which increases with aging (59), perhaps due to an increase in 15-lipoxygenase and free oxygen radicals (21, 60) . Oxidized LDL inhibits osteoblast differentiation in vitro, and administration of a high fat atherogenic diet suppresses bone formation in mice (61, 62) . Based on these lines of evidence, we propose that an increase in the level of LA oxidation products, such as 9-EOA and 9,10-DHOA, might contribute to decreased bone formation during aging. Interestingly, the parent ligand, LA, had no effect on osteoblast or adipocyte differentiation, but modestly decreased Wnt-10b. Thus, the response of our stromal cell model to LA differs from that of the NIH-3T3 cell model (63) , consistent with the idea that responses to PPAR␥2 activation are cell specific.
In summary, we have shown that diverse ligands of PPAR␥2 act as selective PPAR␥2 modulators designated SPPARMs (64) to regulate distinct pathways, the sum of which may lead to full or partial expression of the adipocyte phenotype, suppression of osteoblast differentiation, or both. Future studies are needed to elucidate the pathways that mediate PPAR␥2-induced inhibition of osteoblast differentiation and to identify SPPARMs that can block the adverse effects of PPAR␥2 activation on osteoblast differentiation while retaining other beneficial activities, such as insulin sensitization.
